journal
MENU ▼
Read by QxMD icon Read
search

Current Oncology Reports

journal
https://www.readbyqxmd.com/read/29752600/pancreatic-cancer-metabolism-molecular-mechanisms-and-clinical-applications
#1
REVIEW
Abdel Nasser Hosein, Muhammad Shaalan Beg
PURPOSE OF REVIEW: Pancreatic adenocarcinoma is a leading cause of cancer mortality in western countries with a uniformly poor prognosis. Unfortunately, there has been little in the way of novel therapeutics for this malignancy over the last several decades. Derangements in metabolic circuitry favoring excess glycolysis are increasingly recognized as a key hallmark of cancer. RECENT FINDINGS: The role of alterations in glutamine metabolism in pancreatic tumor progression has been elucidated in animal models and human cells lines, and there has been considerable interest in exploiting these aberrations for the treatment of pancreatic cancer...
May 11, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/29740718/combination-immunotherapy-in-non-small-cell-lung-cancer
#2
REVIEW
Melina E Marmarelis, Charu Aggarwal
PURPOSE OF REVIEW: Checkpoint blockade has changed the treatment landscape in non-small cell lung cancer (NSCLC), but single-agent approaches are effective for only a select subset of patients. Here, we will review the evidence for combination immunotherapies in NSCLC and the clinical data evaluating the efficacy of this approach. RECENT FINDINGS: Clinical trials evaluating combination PD-1 and CTLA-4 blockade as well as PD-1 in combination with agents targeting IDO1, B7-H3, VEGF, and EGFR show promising results...
May 8, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/29736685/emerging-trends-in-the-management-of-brain-metastases-from-non-small-cell-lung-cancer
#3
REVIEW
Thomas M Churilla, Stephanie E Weiss
PURPOSE OF REVIEW: To summarize current approaches in the management of brain metastases from non-small cell lung cancer (NSCLC). RECENT FINDINGS: Local treatment has evolved from whole-brain radiotherapy (WBRT) to increasing use of stereotactic radiosurgery (SRS) alone for patients with limited (1-4) brain metastases. Trials have established post-operative SRS as an alternative to adjuvant WBRT following resection of brain metastases. Second-generation TKIs for ALK rearranged NSCLC have demonstrated improved CNS penetration and activity...
May 7, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/29728940/systemic-therapies-for-advanced-squamous-cell-anal-cancer
#4
REVIEW
Francesco Sclafani, Sheela Rao
PURPOSE OF REVIEW: We aim to summarise the available evidence on systemic therapies for advanced anal cancer. RECENT FINDINGS: There is no universal consensus on the management of this condition and the prognosis remains poor. Nevertheless, significant progress has been recently made including completion of the first, ever-conducted, randomised trial in the first-line setting, investigation of immunotherapy in the refractory setting and use of comprehensive genomic profiling for a better molecular characterisation of this disease and the identification of novel potential targets...
May 4, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/29713898/pharmacogenetics-of-chemotherapy-induced-cardiotoxicity
#5
REVIEW
Vivian Y Chang, Jessica J Wang
PURPOSE OF REVIEW: The goal of this review is to summarize current understanding of pharmacogenetics and pharmacogenomics in chemotherapy-induced cardiotoxicity. RECENT FINDINGS: Most of the studies rely on in vitro cytotoxic assays. There have been several smaller scale candidate gene approaches and a handful of genome-wide studies linking genetic variation to susceptibility to chemotherapy-induced cardiotoxicity. Currently, pharmacogenomic testing of all childhood cancer patients with an indication for doxorubicin or daunorubicin therapy for RARG rs2229774, SLC28A3 rs7853758, and UGT1A6*4 rs17863783 variants is recommended...
April 30, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/29713835/physical-activity-and-breast-cancer-an-opportunity-to-improve-outcomes
#6
REVIEW
Lindsay L Peterson, Jennifer A Ligibel
PURPOSE OF REVIEW: To review current data regarding physical activity and breast cancer including cancer risk, cancer prognosis, treatment-related side effects, and patient-reported outcomes. We will summarize current physical activity guidelines for cancer survivors and discuss opportunities to study and implement physical activity programs in cancer survivors. RECENT FINDINGS: Observational evidence suggests that physical activity is associated with a reduced risk of developing breast cancer, a reduced risk of breast cancer recurrence, and improved breast cancer-specific and all-cause mortality...
April 30, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/29713831/checkpoint-inhibitors-in-the-treatment-of-breast-cancer
#7
REVIEW
Tomas G Lyons, Maura N Dickler, Elizabeth E Comen
PURPOSE OF REVIEW: The treatment landscape for many cancers has dramatically changed with the development of checkpoint inhibitors. This article will review the literature concerning the use of checkpoint inhibitors in breast cancer. RECENT FINDINGS: The histological subtype of BC with the strongest signal of efficacy has been triple-negative breast cancer (TNBC). Early trials of single-agent checkpoint inhibitors did not demonstrate a uniformly positive signal...
April 30, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/29644507/the-impact-of-obesity-on-breast-cancer
#8
REVIEW
Daniel F Argolo, Clifford A Hudis, Neil M Iyengar
The rates of obesity are increasing worldwide and this condition is now recognized as a leading preventable cause of cancer. Several diseases are directly related to obesity, including diabetes, hypertension, atherosclerosis, stroke, musculoskeletal disorders, and a diverse range of malignances-such as breast cancer. Obesity is associated with an increased risk of postmenopausal estrogen receptor-positive breast cancer and worse cancer-related outcomes for all breast tumor subtypes. Several mechanisms have been proposed to contribute to the obesity-cancer link, including high levels of circulating and local estrogens, altered amounts of adipokines (leptin and adiponectin), disrupted insulin/IGF signaling, modifications within the microbiome, and local and systemic effects of inflammation...
April 11, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/29644505/cardiotoxicity-of-immunotherapy-incidence-diagnosis-and-management
#9
REVIEW
Aarti Asnani
PURPOSE OF REVIEW: This review describes cardiotoxicity associated with adoptive T cell therapy and immune checkpoint blockade. RECENT FINDINGS: Cardiotoxicity is a rare but potentially fatal complication associated with novel immunotherapies. Both affinity-enhanced and chimeric antigen receptor T cells have been reported to cause hypotension, arrhythmia, and left ventricular dysfunction, typically in the setting of cytokine release syndrome. Immune checkpoint inhibitors are generally well-tolerated but have the potential to cause myocarditis, with clinical presentations ranging from asymptomatic cardiac biomarker elevation to heart failure, arrhythmia, and cardiogenic shock...
April 11, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/29644490/emerging-role-of-immunotherapy-in-advanced-urothelial-carcinoma
#10
REVIEW
Vadim S Koshkin, Petros Grivas
PURPOSE OF REVIEW: Advanced urothelial carcinoma (aUC) has long been treated preferably with cisplatin-based chemotherapy, but many patients are cisplatin-ineligible whereas for those who progress on a platinum-based regimen treatment options are limited. We review key recent data regarding immune checkpoint inhibitors that are changing this treatment landscape. RECENT FINDINGS: Since May 2016, five different agents targeting the PD-1/PD-L1 pathway (atezolizumab, pembrolizumab, nivolumab, avelumab, durvalumab) have received FDA approval for the treatment of aUC in the platinum-refractory setting, while pembrolizumab and atezolizumab are FDA-approved for cisplatin-ineligible patients in the first-line setting...
April 11, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/29644477/the-selective-use-of-radiation-therapy-in-rectal-cancer-patients
#11
REVIEW
Andrew Martella, Christopher Willett, Manisha Palta, Brian Czito
PURPOSE OF REVIEW: Colorectal cancer has a high global incidence, and standard treatment employs a multimodality approach. In addition to cure, minimizing treatment-related toxicity and improving the therapeutic ratio is a common goal. The following article addresses the potential of omitting radiotherapy in select rectal cancer patients. RECENT FINDINGS: Omission of radiotherapy in rectal cancer is analyzed in the context of historical findings, as well as more recent data describing risk stratification of stage II-III disease, surgical optimization, imaging limitations, improvement in systemic chemotherapeutic agents, and contemporary studies evaluating selective omission of radiotherapy...
April 11, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/29644475/electrophysiologic-toxicity-of-chemoradiation
#12
REVIEW
Merna A Armanious, Shreya Mishra, Michael G Fradley
PURPOSE OF REVIEW: There is growing awareness of the link between oncology treatments and cardiovascular (CV) complications. This has led to the development of cardio-oncology, a specialty aimed at managing CV risk and disease in cancer patients and survivors. Cardiac arrhythmias are potential adverse CV complications of cancer treatments; however, these cardiotoxicities are often underappreciated due to the uncertain arrhythmogenic mechanisms of various chemotherapeutic agents. RECENT FINDINGS: Chemotherapeutic agents can induce arrhythmias via direct electrophysiological effects on ion channels or intracellular signaling pathways, or indirectly from cardiac tissue damage...
April 11, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/29644451/emerging-therapies-in-metastatic-prostate-cancer
#13
REVIEW
Daniel W Sonnenburg, Alicia K Morgans
PURPOSE OF REVIEW: In the last decade, there have been multiple landmark therapeutic advances for the treatment of metastatic prostate cancer, both in the castration-resistant and hormone-sensitive setting. In this review, we highlight recent progress and ongoing trials for metastatic prostate cancer, including advances in chemotherapy, androgen receptor-directed therapy, targeted therapies, and immunotherapy. RECENT FINDINGS: Several landmark studies for men with metastatic hormone-sensitive prostate cancer demonstrated improvement in overall survival with the addition of docetaxel chemotherapy or abiraterone acetate to standard androgen deprivation therapy...
April 11, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/29644450/monitoring-and-management-of-toxicities-of-novel-b-cell-signaling-agents
#14
REVIEW
Joanna Rhodes, Anthony Mato, Jeff P Sharman
PURPOSE REVIEW: B cell signaling agents, including ibrutinib, idelalisib, and the BCL-2 inhibitor venetoclax have become an integral part of therapy for patients with non-Hodgkin's lymphomas. The toxicity profiles of these medications is distinct from chemoimmunotherapy. Here, we will review the mechanism of action of these drugs, their efficacy, and toxicity management. RECENT FINDINGS: Ibrutinib use is associated with increased risk of atrial fibrillation and bleeding which can be managed using dose interruptions and modifications...
April 11, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/29637300/single-cell-rna-sequencing-in-glioma
#15
REVIEW
Eli Johnson, Katherine L Dickerson, Ian D Connolly, Melanie Hayden Gephart
PURPOSE OF REVIEW: In this review, we seek to summarize the literature concerning the use of single-cell RNA-sequencing for CNS gliomas. RECENT FINDINGS: Single-cell analysis has revealed complex tumor heterogeneity, subpopulations of proliferating stem-like cells and expanded our view of tumor microenvironment influence in the disease process. Although bulk RNA-sequencing has guided our initial understanding of glioma genetics, this method does not accurately define the heterogeneous subpopulations found within these tumors...
April 10, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/29611060/targeted-agents-in-cervical-cancer-beyond-bevacizumab
#16
REVIEW
Gloria Marquina, Aranzazu Manzano, Antonio Casado
Cervical cancer constitutes a leading cause of morbidity and cancer deaths in women throughout the world. Approximately two thirds of the patients are diagnosed with locally advanced cervical cancer, showing disappointing survival rates despite correct multidisciplinary management. Metastatic disease implies a poor prognosis itself since diagnosis. Platinum-based chemotherapy has been the backbone treatment of metastatic cervical cancer for years with no major outstanding improvements on survival. The addition of new molecules, such as antiangiogenic agents, dramatically changed the treatment of this disease...
April 2, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/29611002/current-and-emerging-therapeutic-targets-for-metastatic-renal-cell-carcinoma
#17
REVIEW
Kevin Zarrabi, Shenhong Wu
PURPOSE OF REVIEW: The treatment of advanced renal cell carcinoma has evolved dramatically over recent years. In this review, we will summarize current and emerging therapies based on molecular targets and provide insight into treatment strategy for metastatic renal cell carcinoma. RECENT FINDINGS: We have witnessed a paradigm shift in the therapeutic landscape as treatment was formerly reliant on cytokine-based agents which have now been replaced with therapies targeting angiogenesis, mammalian target of rapamycin pathways, and immune responses...
April 2, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/29582218/current-concepts-in-the-treatment-of-resectable-pancreatic-cancer
#18
REVIEW
Marc T Roth, Jordan D Berlin
PURPOSE OF REVIEW: The diagnosis of pancreatic cancer carries with it a high mortality rate. Despite advances in the field, this has remained relatively unchanged over the last few decades. Current options for the treatment of resectable pancreatic ductal adenocarcinoma will be reviewed here in conjunction with the historical data that support them. We will focus on updates in treatment guidelines and ongoing clinical trials of interest. RECENT FINDINGS: For localized disease, standard of care includes resection followed by adjuvant chemotherapy ± chemoradiation...
March 26, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/29582192/prevalence-and-risk-of-polypharmacy-among-elderly-cancer-patients-receiving-chemotherapy-in-ambulatory-oncology-setting
#19
REVIEW
Ivy Goh, Olive Lai, Lita Chew
PURPOSE OF REVIEW: This was a single center, retrospective cross-sectional study looking into the incidence and types of drug-related problems (DRPs) detected among elderly cancer patients receiving at least three long-term medications concurrent with IV chemotherapy, and the types of intervention taken to address these DRPs. This paper serves to elucidate the prevalence and risk of polypharmacy in our geriatric oncology population in an ambulatory care setting, to raise awareness on this growing issue and to encourage more resource allocation to address this healthcare phenomenon...
March 26, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/29582189/mesenchymal-chondrosarcoma-a-review-with-emphasis-on-its-fusion-driven-biology
#20
REVIEW
Marc El Beaino, Jason Roszik, John A Livingston, Wei-Lien Wang, Alexander J Lazar, Behrang Amini, Vivek Subbiah, Valerae Lewis, Anthony P Conley
Mesenchymal chondrosarcoma is a rare but deadly form of chondrosarcoma that typically affects adolescents and young adults. While curative intent is possible for patients with localized disease, few options exist for patients in the unresectable/metastatic setting. Thus, it is imperative to understand the fusion-driven biology of this rare malignant neoplasm so as to lead to the future development of better therapeutics for this disease. This manuscript will briefly review the clinical and pathologic features of mesenchymal chondrosarcoma followed by an appraisal of existing data linked to the fusions, HEY1-NCOA2 and IRF2BP2-CDX1, and the associated downstream pathways...
March 26, 2018: Current Oncology Reports
journal
journal
34702
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"